Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairment (HI) might have increased cobimetinib exposure. By attending this educational activity, you will learn about the impact of HI on the pharmacokinetics (PK) and safety of cobimetinib.

Artificial intelligence (AI) and machine learning (ML) techniques are transforming nearly every sector of our life and the economy, including health care. Artificial intelligence and ML is transforming the way we approach drug discovery, design clinical trials, recommend more personalized treatments and make medications safer. Furthermore, healthcare data are often available to payers and health care systems in real time, but are massive, high dimensional and complex. This presentation gives an overview of basic ML concepts and provides an introduction to a few commonly used ML techniques and their practical applications in pharmaceutical outcomes research. This presentation will also outline and discuss the challenges/limitations and risks relating to the use of real-world data and ML methods.

The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.

Presented by: Luke Delzer, PharmD, Clinical Pharmacist, Kaiser Permanente

Presented by: Alexander Vinks, PharmD, PhD, FCP, Professor and Div Director, Cincinnati Children’s Hosp Medical Ctr, Clinical Pharmacology and Henry Akinbi, MD, Director of Education, Cincinnati Children’s Hosp Medical Ctr, Perinatal Inst